As previously reported, Guggenheim downgraded Acadia Pharmaceuticals (ACAD) to Neutral from Buy with a price target of $20, down from $23. The firm, which views Acadia as fairly valued at current levels due to “the lack of significant pipeline catalysts for 2025,” also lowered its peak sales estimate for Daybue to $730M from $830M.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals downgraded to Neutral from Buy at Guggenheim
- CompoSecure to spin off Resolute, EHang raises Q4 revenue view; Morning Buzz
- Morning Movers: EHang jumps following guidance raise
- Closing Bell Movers: CompoSecure gains 5% on Resolute Holdings spinoff
- Acadia to replace Independent Bank in S&P 600 at open on 1/3